Lilly's orforglipron shows superior weight loss and blood sugar control Highest dose of the pill leads to 9.2% weight reduction Detailed trial results to be presented at future medical meeting The ...

Eli Lilly's shares have increased by about 10% over the past month. Clinical progress in the past few weeks has helped solidify its lead in the weight loss market. The company's prospects remain ...

While Eli Lilly is rethinking its biotech incubator plans in Europe, the Big Pharma has gone ahead and opened its San Diego site. The Gateway Labs are co-working spaces for researchers that also act ...

At this year’s meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Eli Lilly sought to bolster the case for its oral GLP-1 orforglipron, showcasing more of the drug's ...

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons it didn’t disclose. Lilly closed the trial on ...

VIENNA, Sept 17 (Reuters) - Eli Lilly's (LLY.N), opens new tab bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and the company reaffirmed ...

Eli Lilly has won the second FDA approval for an oral selective estrogen receptor degrader (SERD). Like the first oral SERD, Lilly’s imlunestrant is only cleared to treat ER-positive, HER2-negative ...

Eli Lilly has revealed the location of the second of its four large-scale manufacturing facilities that it plans to build in the U.S., selecting Houston as home to a $6.5 billion plant that will ...

The pharmaceutical company Eli Lilly announced on Tuesday that it will build a $6.5 billion facility in Texas, marking the company’s second multibillion-dollar U.S. investment this month. The ...

Eli Lilly's two biggest growth drivers are far from having reached their peak. The company should record significant clinical progress in the next three years. Despite some potential headwinds, the ...

Sept. 23 (UPI) --Indianapolis-based Eli Lilly intends to build a biomanufacturing facility that would cost $6.5 billion to build and employ 4,000 construction workers in the greater Houston area.

Pharmaceutical giant Eli Lilly unveiled plans to build a $6.5 billion biomanufacturing plant in northeast Houston within the next five years, bolstering the region’s bid to become a national ...